ETF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. IShares Nasdaq Biotechnology (IBB), the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as Illumina (ILMN) stumbled.